Software as a Medical Device (SaMD) — Regulatory Frameworks and Compliance
CONCEPTSoftware as a Medical Device (SaMD) is the regulatory category under which AI-enabled clinical tools are classified by the FDA, EU, and other jurisdictions. A comparative governance study (PubMed 41967377) analyzing 43 regulatory documents across five jurisdictions found increasing convergence around core principles — transparency, accountability, and human-centric AI — but significant divergence in regulatory maturity, enforcement mechanisms, reimbursement pathways, and implementation capabilities. Singapore and China exhibit centralized, state-led coordination; the US reflects a pluralistic, agency-driven model. The EU regulatory framework for AI in radiology (PubMed 41832928) incorporates the 2017 Medical Device Regulation (MDR), the 2018 GDPR, and the 2024 AI Act's risk-based approach. For the US, FDA premarket pathways (510(k), De Novo, PMA) are supplemented by recent regulations on lifecycle management, post-marketing surveillance, and adaptive algorithms. China's 2022 NMPA guidance classifies AI medical software by risk level, with mandatory de-identification for manufacturers. All three jurisdictions show convergence on data protection, risk classification, transparency, explainability, and human oversight requirements. South Africa's Health Professions Council published Booklet 20 — its first ethical framework for AI in healthcare (PubMed 42246861) — which is being critically evaluated against national legislation, the Protection of Personal Information Act, and the…
Subscribe to read full wiki analysis
Full wiki content — including source provenance, contradiction tracking, related pages, and analyst notes — is available to Subscriber members.
View Plans & SubscribeNew users get a 7-day trial — no credit card required.